Barry D. Quart - 13 Jul 2022 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lisa Peraza Attorney-in-fact for Barry D. Quart
Issuer symbol
HRTX
Transactions as of
13 Jul 2022
Transactions value $
-$9,931
Form type
4
Filing time
15 Jul 2022, 16:57:44 UTC
Previous filing
30 Jun 2022
Next filing
17 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Other $5.78K +1.5K +1.15% $3.84 133K 29 Apr 2022 Direct F1
transaction HRTX Common Stock Options Exercise +3.65K +2.75% 136K 13 Jul 2022 Direct F2
transaction HRTX Common Stock Options Exercise +16.1K +11.83% 152K 13 Jul 2022 Direct F2
transaction HRTX Common Stock Tax liability -$15.7K -5.22K -3.42% $3.01 147K 13 Jul 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -3.65K -10% $0.00 32.8K 13 Jul 2022 Common Stock 3.65K Direct F2, F4
transaction HRTX Restricted Stock Units Options Exercise $0 -16.1K -9.88% $0.00 147K 13 Jul 2022 Common Stock 16.1K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F4 The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F5 The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).